Findings

What do systematic reviews say?

4 questions · 4 findings · 4 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 2 · 50%Low 2 · 50%Moderate 0 · 0%High 0 · 0%

Naftopidil vs Eviprostat (phytotherapy)

Withdrawals due to adverse events

It is very uncertain whether naftopidil changes treatment withdrawals due to adverse events compared with eviprostat (phytotherapy) (very low certainty).

1 finding from 1 review

Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 49 participants
Very low

Evening vs morning dosing regimen

Withdrawals due to adverse events · adults with primary (essential) hypertension whose systolic or diastolic (or both) blood pressure levels were 130/80 mmHg or greater

It is very uncertain whether evening changes withdrawals from treatment due to adverse events compared with morning dosing regimen (very low certainty).

1 finding from 1 review

Evening versus morning dosing regimen drug therapy for hypertension 2024 · Cochrane Headline outcomes only
RR 0.76 [0.47, 1.23]
7 studies · 1777 participants
Very low

Shock wave therapy vs placebo

Number of participant withdrawals due to adverse events or treatment intolerance · rotator cuff disease

Shock wave therapy showed no clear difference in number of participant withdrawals due to adverse events or treatment… compared with placebo (low certainty).

1 finding from 1 review

Shock wave therapy for rotator cuff disease with or without calcification 2020 · Cochrane Headline outcomes only
RR 0.75 [0.43, 1.31]
7 studies · 581 participants
Low

Calcium channel blockers vs placebo

Withdrawals due to adverse events · patients with Raynaud's phenomenon

Calcium channel blockers showed no clear difference in number of withdrawals due to adverse events Number of participants… compared with placebo (low certainty).

1 finding from 1 review

Calcium channel blockers for primary and secondary Raynaud's phenomenon 2017 · Cochrane Headline outcomes only
RR 1.3 [0.51, 3.33]
2 studies · 63 participants
Low